Supporting patient groups and continuously improving knowledge in our therapy areas is part of our corporate responsibility.
Our ultimate goal is to discover and develop innovative therapies to improve patients' quality of life.
We specialize in the treatment of life-threatening diseases. Our patients always come first.
We offer programs for patients, families and patient organizations worldwide. They help to improve the quality of medical care.
Our product pipeline focuses on innovation and improving therapies.
Welcome to the Research & Development Team in Marburg.
At CSL Behring, we work every day as if someone’s life depends on it, because it does.
CSL Behring's biotherapeutics are manufactured in state-of-the-art facilities under strictly controlled conditions.
Help us deliver on our promise to save lives and protect the health of people.
We want you to feel comfortable at CSL.
Get to know us and learn more about people, projects and what happens in the world of CSL Behring.
Information for the press, such as press releases and press contact.
The regional initiative is committed to harmonizing economy, ecology and social issues.
500 Million IUs Coagulation Factor Replacement Therapy for the World Federation of Hemophilia Humanitarian Aid Program
On Word Hemophilia Day we reaffirm our mission to create best-in-calss treatments for haemophilia
More than a century of scientific research and discovery
EMA Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
Call for proposals for CSL Behring DACH Region 2022.
Under the motto "Share Your Colors", we are setting an example for the 300 million people living with a rare disease.
We chatted with mother-and-son team Evren and Kara Ayik, authors of a new book that’s for, and about, kids who have rare dise…
Supporters hope a newly adopted U.N. resolution will make rare disease patients more visible and ensure they have access to c…
Popular search terms:
Americas
Asia Pacific
Middle East
Europe
